Balyasny Asset Management’s ClearPoint Neuro CLPT Stock Holding History

Balyasny Asset Management’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$892	Buy	+50	New	+$625	﹤0.01%	2950
2026 Q1	–	Sell	-217,274	Closed	-$2.97M	–	2957
2025 Q4	$2.97M	Buy	+217,274	New	+$4.03M	﹤0.01%	1671
2025 Q2	–	Sell	-51,737	Closed	-$615K	–	2888
2025 Q1	$615K	Buy	51,737 +34,463	+200%	+$536K	﹤0.01%	2198
2024 Q4	$266K	Buy	+17,274	New	+$224K	﹤0.01%	2437
2023 Q1	–	Sell	-14,361	Closed	-$122K	–	2709
2022 Q4	$122K	Buy	+14,361	New	+$136K	﹤0.01%	2222

Other funds holding CLPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lane Generational Dover, Massachusetts $114M AUM 43.8% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

CFM

Compass Financial Management Tampa, Florida $829M AUM

Balyasny Asset Management's CLPT Position: Q2 2026 in Review

Balyasny Asset Management opened a new position in ClearPoint Neuro (CLPT) in Q2 2026: 50 shares worth $892. The stake represents ﹤0.01% of the portfolio and ranks #2950 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in CLPT as recently as Q4 2025.

Balyasny Asset Management first reported a position in CLPT in Q4 2022 and has held it in 5 quarters since. The position peaked at $2.97M in Q4 2025. 129 funds tracked by Wall St. Rank hold CLPT as of Q2 2026.

Balyasny Asset Management held 50 shares of ClearPoint Neuro worth $892 as of Q2 2026.
ClearPoint Neuro was a new Balyasny Asset Management position in Q2 2026.
ClearPoint Neuro made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #2950 holding.
Balyasny Asset Management first reported a position in ClearPoint Neuro in Q4 2022 and has held it in 5 quarters since.
Balyasny Asset Management's ClearPoint Neuro position peaked at $2.97M in Q4 2025.
129 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.